GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis

Cell Physiol Biochem. 2017;42(3):1165-1176. doi: 10.1159/000478872. Epub 2017 Jun 30.

Abstract

Background/aims: The aim of this study was to determine the direct role of liraglutide (LG) in adipogenesis and lipid metabolism.

Methods: Lipid accumulation was evaluated by oil red O staining, quantitative real-time PCR (qPCR) was performed to determine glucagon-like peptide 1 receptor (GLP-1R), fatty acid synthase (FASN) and adipose triglyceride lipase (ATGL) expression in 3T3-L1 preadipocytes, differentiated adipocytes and in adipose tissues from mice. The effects of LG on 3T3-L1 adipogenesis and lipid metabolism were analyzed with qPCR, Western Blotting, oil red O staining, immunohistochemistry (IHC) and immunofluorescence (IF). All measurements were performed at least three times.

Results: LG increased the expression of differentiation marker genes and lipid accumulation during preadipocyte differentiation. In differentiated adipocytes, LG decreased FASN expression, and simultaneously led to CREB phosphorylation and ERK1/2 activation which were abolished by a GLP-1R antagonist, exendin (9-39). LG induced-FASN down-regulation was partially reversed by PKA and ERK1/2 inhibitors. Consistent with above in vitro findings, LG treatment significantly reduced FASN expression in visceral adipose tissues of ob/ob mice, and reduced body weight gain.

Conclusion: LG promotes preadipocytes differentiation, and inhibits FASN expression in adipocytes. LG induced down-regulation of FASN is at least partially mediated by PKA and MAPK signaling pathways.

Keywords: 3T3-L1 preadipocytes; Adipogenesis; FASN; Liraglutide.

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / cytology
  • Adipocytes / drug effects*
  • Adipocytes / metabolism
  • Adipogenesis / drug effects*
  • Animals
  • Down-Regulation / drug effects
  • Fatty Acid Synthase, Type I / genetics
  • Fatty Acid Synthase, Type I / metabolism
  • Glucagon-Like Peptide 1 / genetics
  • Glucagon-Like Peptide 1 / metabolism*
  • Glucagon-Like Peptide-1 Receptor / genetics
  • Glucagon-Like Peptide-1 Receptor / metabolism*
  • Hypoglycemic Agents / pharmacology*
  • Lipogenesis / drug effects*
  • Liraglutide / pharmacology*
  • Mice
  • Signal Transduction / drug effects

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Liraglutide
  • Glucagon-Like Peptide 1
  • Fatty Acid Synthase, Type I